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Abstract
Background: The presence of cancer-specific DNA methylation patterns in epithelial colorectal cells in human
feces provides the prospect of a simple, non-invasive screening test for colorectal cancer and its precursor, the
adenoma. This study investigates a panel of epigenetic markers for the detection of colorectal cancer and
adenomas.
Methods: Candidate biomarkers were subjected to quantitative methylation analysis in test sets of tissue samples
from colorectal cancers, adenomas, and normal colonic mucosa. All findings were verified in independent clinical
validation series. A total of 523 human samples were included in the study. Receiver operating characteristic (ROC)
curve analysis was used to evaluate the performance of the biomarker panel.
Results: Promoter hypermethylation of the genes CNRIP1, FBN1, INA, MAL, SNCA, and SPG20 was frequent in both
colorectal cancers (65-94%) and adenomas (35-91%), whereas normal mucosa samples were rarely (0-5%)
methylated. The combined sensitivity of at least two positives among the six markers was 94% for colorectal
cancers and 93% for adenoma samples, with a specificity of 98%. The resulting areas under the ROC curve were
0.984 for cancers and 0.968 for adenomas versus normal mucosa.
Conclusions: The novel epigenetic marker panel shows very high sensitivity and specificity for both colorectal
cancers and adenomas. Our findings suggest this biomarker panel to be highly suitable for early tumor detection.
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Background
Colorectal cancer is the third most common cancer type
in the US and is a major contributor to cancer-death
[1]. Most cases of colorectal cancer develop from benign
precursors (adenomas) during a long time interval. This
provides a good opportunity for detection of colorectal
cancer at an early curable stage and to screen for poten-
tially pre-malignant adenomas [2]. Both flexible sigmoi-
doscopy and the Fecal Occult Blood Test (FOBT) have
been tested in randomized trials and shown to reduce
mortality from colorectal cancer [3]. By sigmoidoscopy
adenomas may be detected and removed and thus the
incidence of cancer will be reduced [4], however, this
screening is invasive and cumbersome for the patient.
FOBT on the other hand is non-invasive and currently
the most commonly used screening test for colorectal
cancer in Europe. Although the sensitivity and specifi-
city measurements of FOBT have been substantially
improved in recent years [5], they are still not optimal.
FOBT is also hampered by the low sensitivity for adeno-
mas. Therefore, during recent years, much effort has
been put in the development of fecal DNA markers. A
successful biomarker panel that is able to discriminate
between healthy individuals and carriers of early color-
ectal cancer or precursor lesions has the potential of
reducing both incidence and mortality of the disease.
* Correspondence: rlothe@rr-research.no
1Department of Cancer Prevention, Institute for Cancer Research, Oslo
University Hospital - Radiumhospitalet, Oslo, Norway
Full list of author information is available at the end of the article
Lind et al. Molecular Cancer 2011, 10:85
http://www.molecular-cancer.com/content/10/1/85
© 2011 Lind et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Until today, however, no feces DNA test has achieved a
satisfactory performance level compared to the screen-
ing tests mentioned above.
Aberrant DNA promoter methylation has previously
been shown to be an early event in the development of
colorectal cancer [6-10]. Several reports of DNA methy-
lation biomarkers tested in fecal [8,11-15] and blood
samples [16-19] suggest the suitability of epigenetic bio-
markers in early diagnostics of the disease. However,
only markers which provide a high methylation fre-
quency in samples from colorectal cancer patients and
at the same time lack hypermethylation in normal
mucosa are suitable for a screening test.
T h ep r e s e n ts t u d yr e p o r t so nt h ep e r f o r m a n c e( t h e
sensitivity and specificity) of a novel epigenetic biomar-
ker panel.
Methods
Selection of epigenetic markers analyzed in the present
study
From an epigenomic screen of colon cancer in vitro
models we have previously identified a number of genes
responding to 5-aza-2’deoxycytidine treatment [20]. In
the present study, thirteen of these candidates were ana-
lyzed in 20 colon cancer cell lines in order to identify
the most suitable DNA methylation markers for colorec-
tal cancer (Table 1, Figure 1). From this analysis we
selected CNRIP1, FBN1, INA,a n dSNCA for detailed
studies in clinical sample series using quantitative MSP
(qMSP) assays. Additionally, a qMSP assay was designed
and applied for analysis of the MAL gene promoter, pre-
viously reported by us as a biomarker for early detection
of colorectal tumors by qualitative MSP [21,22]. Finally,
the SPG20 biomarker recently reported with a sensitivity
of 89% and 78% in colorectal cancer and adenomas,
respectively and a specificity of 99% [9] was included for
evaluation of a combined biomarker panel performance.
Cancer Cell Lines
Nine of the 20 colon cancer cell lines were microsatel-
lite unstable, MSI (Co115, HCT15, HCT116, LoVo,
LS174T, RKO, SW48, TC7, and TC71), and 11 were
microsatellite stable, MSS (ALA, Colo320, EB, FRI,
HT29, IS1, IS2, IS3, LS1034, SW480, and V9P) [23].
Culturing conditions included DMEF-12 medium
(GIBCO, Invitrogen Carlsbad, CA) with 15% fetal bovine
serum (GIBCO, 2 mM L-glutamine (GIBCO), 100 U/ml
penicillin G, and 100 μg/ml streptomycin (GIBCO).
Three MSI cell lines (HCT15, RKO, and SW48) and
three MSS cell lines (HT29, LS1034, and SW480) were
treated with a) 1 μMo f5 - a z a - 2 ’deoxycytidine (Sigma-
A l d r i c h ,S t .L o u i s ,M O ,U S A )f o r7 2h ,b )0 . 5μMo f
Table 1 Names, chromosomal location, and sequence accession number for genes analyzed in the present study
Gene Symbol
a Gene Name
a Chromosomal Location
a Accession Number
b
BEX1 brain expressed, X-linked 1 Xq21-q23 NM_018476
C3orf14 chromosome 3 open reading frame 14 3 NM_020685
CNRIP1 cannabinoid receptor interacting protein 1 2p13 NM_015463
COL15A1 collagen, type XV, alpha 1 9q21-q22 NM_001855
FBN1 fibrillin 1 15q21.1 NM_000138
FERMT2 fermitin family homolog 2 (Drosophila) 14q22.1 NM_006832
FHL1 four and a half LIM domains 1 Xq26.3 NM_001449
INA internexin neuronal intermediate filament protein, alpha 10q24 NM_032727
KCNQ2 potassium voltage-gated channel, KQT-like subfamily, member2 20q13.33 NM_172106
LEF1 lymphoid enhancer-binding factor 1 4q23-q25 NM_016269
MEF2C myocyte enhancer factor 2C 5q14 NM_002397
SNCA synuclein, alpha (non A4 component of amyloid precursor) 4q21.3-q22 NM_000345
UBE3A ubiquitin protein ligase E3A 15q11-q13 NM_130839
aGene Symbols, full Gene Name, and Chromosome location are in accordance with the approved guidelines from the HUGO Gene Nomenclature Committee at
the European Bioinformatics Institute, http://www.genenames.org
bSequence Accession Numbers are from the USCS Genome Browser http://genome.ucsc.edu/ and represent sequences used for primer design.
Figure 1 DNA promoter hypermethylation status of 13
candidate genes in colon cancer cell lines. Colon cancer cell
lines were used as in vitro models to explore the DNA promoter
methylation frequency of 13 candidate biomarkers. Only candidates
with methylation frequencies equal to or higher than 80% (CNRIP1,
INA, BEX1, FBN1, SNCA, and C3orf14) were subjected to methylation
analysis in tissue samples.
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nation of both drugs (1 μM 5-aza-2’deoxycytidine for 72
h, 0.5 μM trichostatin A added the last 12 h). The med-
ium was exchanged daily.
Twenty-nine additional cell lines from various cancer
tissues other than colon cancer were included (described
in Additional file 1). All cell lines were harvested before
reaching confluence. DNA was extracted from the can-
cer cell lines by using a standard phenol-chloroform
procedure [24], and total RNA was isolated using Trizol
(Invitrogen, Carlsbad, CA).
Colorectal cancer and adenoma samples
The colorectal cancer test set comprised DNA from 79
fresh-frozen cases from 78 patients derived from a pro-
spective series from seven hospitals in South-East Nor-
way during 1987-1989 [25]. Twenty-eight tumors were
MSI, and 51 were MSS [26,27]. The median patient age
at diagnosis was 71 years (range 33-92 years). One
patient fulfilled the criteria for hereditary non-polyposis
colorectal cancer (HNPCC) [26]. The colorectal cancer
validation set consisted of an independent cohort of 105
cases obtained from a prospective series of fresh-frozen
colorectal cancer samples at the Department of Surgery,
at Oslo University Hospital - Aker Hospital in the per-
iod of 2005-2007. Twenty-two out of 105 (21%) cancers
were MSI-high, whereas the remaining 83 (79%) samples
were of the MSS or MSI-low phenotype. The median
patient age at surgery was 71 years (range 29-93 years).
A series of 61 adenomas was obtained from 50 indivi-
duals attending a population-based colonoscopy screen-
ing study (Telemark, Norway) [28]. The median age at
adenoma removal was 67 years (range 62-72 years) and
the median adenoma size was 8 mm (range 5-50 mm).
Two of the adenomas were MSI whereas the remaining
59 were MSS [20]. The validation set comprised 51 ade-
nomas from 46 individuals attending another screening
study [29]. The median age at adenoma removal was 58
years (range 50-64 years) and the median adenoma size
was 11 mm (range 4-40 mm).
Normal colorectal tissue samples
Two cohorts of normal colorectal mucosa samples were
analyzed. The test set consisted of 51 samples from 48
deceased colorectal cancer-free individuals collected at
the Institute of Forensic Medicine, University of Oslo.
The median age was 55 years (range 22-86 years). The
validation set consisted of rectal mucosa biopsies from
59 individuals attending the population-based colono-
scopy screening study mentioned above, harboring
neither colorectal adenomas nor cancers [28]. The med-
ian age was 67 years (range 63-72 years). Also, 105 nor-
mal colorectal mucosa samples taken from the resection
margin of the colorectal cancer validation series were
included in the present study. Median age for these was
71 years.
Bisulfite Treatment
DNA (1.3 μg) from each tissue sample was bisulfite trea-
ted using the EpiTect bisulfite kit (Qiagen) according to
the manufacturer’s protocol. The desulfonation and
washing steps were performed using a QiaCube
(Qiagen).
Qualitative methylation-specific polymerase chain
reaction (MSP)
Qualitative methylation-specific polymerase chain reac-
tion (MSP) primers were designed using Methyl Primer
Express v1.0 (Applied Biosystems, Foster City, CA,
USA) according to the following criteria: primers ampli-
fied a region within 300 bases of the annotated tran-
scription start site (UCSC Genome Browser [30]), the
maximum fragment length was 200 bp, each primer
contained a minimum of two CpG sites, all primer pairs
contained a minimum of five Cs in non-CpG sites, and
all forward primers had a 3’-proximal CpG site. Primers
were purchased from MedProbe (MedProbe, Oslo, Nor-
way) and their sequences are listed in Additional file 1,
Table S1, along with the product fragment lengths, pri-
mer locations, MgCl2 reaction concentration, and PCR
annealing temperature. The MSP templates were ampli-
fied using the HotStarTaq DNA polymerase (Qiagen).
Human placental DNA (Sigma-Aldrich) treated in vitro
with Sss1 methyltransferase (New England Biolabs, Ips-
wich, MA, USA) was used as a positive control for the
methylated MSP reaction, whereas DNA from normal
lymphocytes was used as a positive control for the
unmethylated reaction. In both reactions we used water
as a negative control. PCR products were separated by
electrophoresis using 2% agarose and visualized by UV
irradiation using a Gene Genius (Syngene, Frederick,
MD, USA). All results were confirmed by a second inde-
pendent round of MSP and scored independently by two
authors (SAD and GEL). A third independent MSP was
done for samples with diverging results or discrepant
scoring from the two initial runs. For each gene, the
MSP controls were sequenced in order to verify the
identity of the amplified product.
Quantitative methylation-specific polymerase chain
reaction (qMSP)
CNRIP1, FBN1, INA, MAL, and SNCA promoter methy-
lation were analyzed by qMSP in the test and validation
sets as well as in stool samples. SPG20 has previously
been reported [9]. Primers and probes were designed
using Primer express v3.0 (Applied Biosystems) and pur-
chased from MedProbe (MedProbe, Oslo, Norway) and
Applied Biosystems, respectively. Sequences are listed in
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FAM and a minor groove binder non-fluorescent
quencher. All genes were amplified and normalized for
DNA input using the ALU-C4 sequence [31]. The qMSP
was carried out in triplicates in 384-well plates using a
20 μl reaction volume including 0.9 μM each of forward
and reverse primers, 0.2 μM probe, 30 ng bisulfite trea-
ted template (tissue samples) or 1 ul bisulfite treated
template (stool sample), and 1 × TaqMan Universal
PCR master mix NoAmpErase UNG (including Ampli-
T a qG o l dD N Ap o l y m e r a s ea n dp a s s i v er e f e r e n c e ;
ROX). Fragments were amplified at 95°C for 10 min,
then 45 cycles of 95°C for 15 sec followed by 60°C for 1
min using the 7900HT Sequence Detection System
(Applied Biosystems). The median value was used for
data analysis. Bisulfite-converted completely methylated
DNA (CpGenome Universal Methylated DNA; Millipore
Billerica, MA, USA) served as a positive control for the
qMSP reaction and 1:5 serial dilutions (32.5 - 0.052 ng)
were used to generate a standard curve for quantifica-
tion. Additionally, all plates contained multiple water
blanks, bisulfite modified DNA from normal lympho-
cytes as well as unmodified DNA as a negative control.
For all samples, amplification after cycle 35 was cen-
sored, in accordance with the protocol from the manu-
facturer (Applied Biosystems). The qMSP results were
calculated as percent of methylated reference (PMR) in
accordance with a previous report [32]. In brief, the
median GENE:ALU ratio of a sample was divided by the
median GENE:ALU ratio of the positive control (CpGe-
nome Universally Methylated DNA) and multiplied by
100. To ensure high specificity for tissue samples, the
percentile of the highest PMR value across all genes and
all normal mucosa samples in the test set was used to
s e taf i x e dt h r e s h o l d( a tP M R=7 )f o rs c o r i n gp o s i t i v e
methylation, regardless of the gene in question. This
scoring threshold was used in analyses of all tissue sam-
ples, including normal mucosa, adenomas and carcino-
mas in both the test and validation sets. Three samples
had outlier PMR values (CNRIP1, 12.41; FBN1, 12.00;
and MAL, 12.22) that were excluded when the fixed
threshold was set. The validation sets and the normal
mucosa samples matching the CRC validation set were
analyzed in a blinded manner.
Direct bisulfite DNA sequencing
DNA bisulfite primers were designed using Methyl Pri-
mer Express v1.0 (Applied Biosystems) according to the
following criteria: sequences covered the area amplified
by the MSP primers of the respective gene promoter
including the transcription start point, maximum frag-
ment length was 450 bp, preferably none and maximum
two CpG sites were included in each primer, and when
possible, repetitive sequences of more than eight bases
were avoided. Primer sequences, product fragment
lengths, primer locations, MgCl2 reaction concentration,
and PCR annealing temperatures are listed in Additional
file 1, Table S1. A representative promoter region of
CNRIP1, FBN1, INA,a n dSNCA was subjected to direct
bisulfite sequencing in 20 colon cancer cell lines, as pre-
viously described [22]. The approximate amount of
methyl cytosine of each CpG site was calculated by
comparing the peak height of the cytosine signal with
the sum of the cytosine and thymine peak height signals
[33]. CpG sites with ratios ranging from 0-0.20 were
classified as unmethylated, CpG sites within the range
0.21-0.80 were classified as partially methylated, and
CpG sites ranging from 0.81-1.0 were classified as
hypermethylated.
RNA isolation, cDNA preparation, and real-time
quantitative gene expression analysis
Total RNA was extracted from cancer cell lines (n =
47), colorectal cancers (CRC test set; n = 17), and nor-
mal colorectal tissue (taken from the resection margin
of the CRC test set; n = 3) samples using Trizol (Invi-
trogen, Carlsbad, CA, USA). RNA from 16 additional
colorectal cancer samples (CRC test set) was extracted
using AllPrep DNA/RNA Mini Kit (Qiagen). The RNA
quality was measured using a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA) and the concentra-
tion was determined using ND-1000 Nanodrop (Nano-
Drop Technologies, Wilmington, DE, USA).
Total RNA was converted to cDNA using the High-
Capacity cDNA Archive kit (Applied Biosystems),
including random primers. The cDNA of CNRIP1
(Hs00384403_m1), FBN1 (Hs00171191_m1), INA
(Hs00190771_m1), SNCA (Hs00240906_m1), and the
endogenous controls ACTB (Hs99999903_m1) and
GUSB (Hs99999908_m1) was amplified separately in
384 well plates according to the manufacturers’ protocol
(Applied Biosystems), and the resulting quantitative
gene expression measurements were registered by the
7900HT Sequence Detection System (Applied Biosys-
tems). Samples were analyzed in triplicates, and the
median value was used for data analysis. The human
universal reference RNA (containing a mixture of total
RNA from ten different cell lines; Agilent) was used to
generate a standard curve, and the resulting quantitative
expression levels of CNRIP1, FBN1, INA,a n dSNCA
were normalized against the mean value of the two
endogenous controls.
Ethics
According to National legislation all samples belong to
approved research biobanks and approvals are given by
the Regional Ethics Committee (S-09282c2009/4958 bio-
bank 2781;S95151).
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For statistical analyses, SPSS 16.0 (SPSS, Chicago, IL,
USA) was used. Pearson’s chi-square and Fisher’s exact
tests were used for categorical variables. Student T-test
and Mann-Whitney U test were used to investigate
potential associations between tumor DNA methylation
and patient age and polyp size. Student T-test was also
used to examine the relationship of aberrant promoter
methylation to gene expression in tissue samples and
cancer cell lines. All P values derive from two-tailed
tests. Receiver Operating Characteristics (ROC) curves
for individual biomarkers were generated using percen-
tage methylated reference (PMR) values and tissue type
(cancer or adenoma and normal) as input. For evalua-
tion of the combined biomarker panel the sum of PMR
values from CNRIP1, FBN1, INA, MAL, SNCA,a n d
SPG20 was used.
Results
Identification of the most suitable biomarkers
In the evaluated 20 colon cancer cell lines, all but one
(UBE3A) gene promoters were hypermethylated with
frequencies ranging from 20% (LEF1 and MEF2C)t o
100% (CNRIP1; Figure 1, and Additional file 2, Figure
S1). Six genes (BEX1, C3orf14, CNRIP1, FBN1, INA,a n d
SNCA) were methylated in > 80% of the cell lines, repre-
senting promising biomarkers in terms of sensitivity.
These were subjected to further detailed analyses in
parts of the colorectal cancer (n = 51) and normal tissue
(n = 21) test sets using qualitative MSP analysis. As
shown in Figure 2, for all genes the frequency of promo-
ter methylation was significantly higher in cancers com-
pared to the normal tissue samples. Methylation in
colorectal cancers ranged from 55% (C3orf14) to 96%
(BEX1; median 84%), while methylation in normal tissue
was between 0% (CNRIP1, FBN1, INA) and 45% (BEX1;
median 5%), P <0 . 0 0 0 1t oP < 0.02. To increase the
likelihood of identifying biomarkers with tumor specific
methylation, only gene promoters with methylation fre-
quencies equal to or lower than 10% in normal samples
(CNRIP1, FBN1, INA,a n dSNCA) were subjected to
further analyses.
Quantitative DNA methylation analyses in test sets:
cancers, adenomas, and normal colorectal samples
CNRIP1, FBN1, INA, MAL, and SNCA promoter methy-
lation was analyzed quantitatively (qMSP) in the color-
ectal cancer (n = 74; median age 71 years) and normal
mucosa (n = 51; median age 55 years) test sets. We
found overall methylation percentages of 99, 81, 66, 92,
and 73 in colorectal cancers and 2, 2, 0, 2, and 0 in nor-
mal mucosa, respectively (Table 2). Quantitative data for
SPG20 [9] was included in a biomarker panel evaluation.
Co-methylation, here defined as simultaneous hyper-
methylation of two or more of the six gene promoters
(CNRIP1, FBN1, INA, MAL, SNCA,a n dSPG20), was
found in 99% of the colorectal cancer test set samples
and 2% of the normal mucosa samples. ROC curves of
the six biomarkers combined resulted in an area under
the ROC curve (AUC) value of 0.999 (Additional file 1,
Table S3).
Within 60 adenoma samples (median age 67 years)
successfully amplified by qMSP, promoter hypermethy-
lation was detected in 90%, 68%, 42%, 85% and 55% for
CNRIP1, FBN1, INA, MAL,a n dSNCA, respectively, and
90% of the adenomas harbored co-methylation. ROC
curves of the combined biomarker panel gave an AUC
value of 0.981 in adenomas versus normal mucosa test
set (Additional file 1, Table S3). The 105 normal
mucosa samples (median age 71 years) taken from the
resection margins of the cancer specimens in the color-
ectal cancer validation set showed promoter methylation
in 40%, 2%, 0%, 3%, and 0% of the same genes, and 4%
harbored co-methylation.
DNA methylation analyses in validation series
The frequencies of methylation in the validation series
were comparable with the findings in the test set (Table
2). Ninety-five out of 105 colorectal cancers (90%; median
age 71 years) and 49 out of 51 adenomas (96%; median
age 58 years) were hypermethylated in at least two of the
six analyzed markers, in contrast to one of the 59 normal
mucosa samples (2%; median age 67 years). The distribu-
tion of PMR values in the normal mucosa samples, the
adenomas, and cancers is illustrated in Figure 3. The AUC
Figure 2 Summary of promoter methylation status in test sets of colorectal cancer and normal colorectal tissue. Red color indicates
methylated sample, green color indicates unmethylated sample, and grey color indicates samples that were not successfully amplified and
thereby not scorable. Gene promoters in the upper panel (CNRIP1, FBN1, INA and SNCA) were methylated in 10% or less of the normal tissue
samples tested and represent biomarkers with potentially high specificities, and thus suitable for a future diagnostic test. Gene promoters in the
lower panel (C3orf14 and BEX1) were methylated more frequently than 10% in normal tissue samples, which might limit the specificity in a test
situation, and were excluded from further analyses.
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cancers versus normal mucosa and 0.962 for adenomas
versus normal mucosa (Additional file 1, Table S3).
Associations of genetic and clinico-pathologic data with
tumor methylation of individual genes
A c r o s st h et e s t( n=7 4 )a n dv a l i d a t i o n( n=1 0 5 )s e r i e s ,
33 out of 179 (18%) colorectal cancers harbored a BRAF
mutation in exon 15. In 23 out of 48 colorectal cancer
cases with microsatellite instability (MSI-high; 48%), a
BRAF mutation in exon 15 was present, compared to
only 10 out of 131 (8%) of the MSS/MSI-low tumors (P
= 8.9E-9).
Methylation of the individual genes was more com-
mon among proximal, MSI-high, and BRAF mutated
cancers, although not statistically significant for all com-
parisons. DNA methylation of each gene was equally
frequent in colorectal cancers of all stages (I-IV) as well
as in tumors from female and male patients (Table 3).
The age of patients with an INA methylation positive
cancer was slightly higher (mean 72 years) than that of
patients with an INA methylation negative cancer (mean
65 years; P = 1.4E-4; T-test). However, all normal color-
ectal samples tested (n = 215) contained unmethylated
INA promoters, ruling out age-specific methylation.
Among the adenomas, INA and FBN1 methylation
w a sm o r ef r e q u e n t l yf o u n di nl a r g e( 1 0m mo rl a r g e r )
than in small adenomas (smaller than 10 mm in dia-
meter; P =0 . 0 1 2a n dP = 0.047, respectively; T-test).
Additional detailed information about clinical associa-
tions is presented in Table 4.
Associations of genetic and clinico-pathologic tumor
sample data with a combined biomarker panel
Co-methylation of two out of six genes (CNRIP1, FBN1,
INA, MAL, SNCA,a n dSPG20)w a sn o ta s s o c i a t e dw i t h
patient gender, and neither with cancer stage, proximal
or distal location, nor BRAF and MSI status (Table 3).
A Mann-Whitney U analysis showed a non-significant
trend (P = 0.067) towards higher age among colorectal
cancer patients positive for the biomarker panel com-
pared with negative patients, but this was not confirmed
in the other sample series (adenomas, normal mucosa,
and normal mucosa from cancer patients). All colorectal
cancers that harbored BRAF mutation as well as the
vast majority (98%) of cancers with the MSI phenotype
were biomarker panel positive, in line with the CIMP
concept [34]. The biomarker panel was additionally
positive in 111/121 (92%) cancers harboring the MSS/
MSI-low phenotypes and wild-type BRAF (Figure 4).
Cancers located in the colon, and particularly the distal
colon, showed somewhat more frequent co-methylation
than did cancers located in the rectum (P = 0.011). The
combined biomarker panel reached an AUC value of
0.984 across the colorectal cancer validation and test
sets (P = 1.9E-43; Figure 5; Additional file 1, Table S3).
The biomarker panel was also positive in adenomas inde-
pendent of clinico-pathological characteristics as there was
Table 2 Methylation frequencies in the analyzed sample cohorts assessed by quantitative methylation-specific
polymerase chain reaction
Samples/Biomarkers CNRIP1 FBN1 INA SNCA MAL SPG20
§ Biomarker
panel
†
Colon Cancer Cell Lines* 20/20 (100%) 18/20 (90%) 19/20 (95%) 18/20 (90%) 19/20 (95%) 20/20 (100%) 20/20 (100%)
Adenomas Test Set 54/60 (90%) 41/60 (68%) 25/60 (42%) 33/60 (55%) 51/60 (85%) 45/60 (75%) 54/60 (90%)
Adenomas Validation Set 47/51 (92%) 36/51 (71%) 14/51 (27%) 26/51 (51%) 42/51 (82%) 42/51 (82%) 49/51 (96%)
Adenomas Combined (Test and
Validation Sets)
101/111
(91%)
77/111
(69%)
39/111
(35%)
59/111
(53%)
93/111
(84%)
87/111
(78%)
103/111
(93%)
CRC Test Set 73/74 (99%) 60/74 (81%) 49/74 (66%) 54/74 (73%) 68/74 (92%) 67/74 (91%) 73/74 (99%)
CRC Validation Set 96/105 (91%) 82/105 (78%) 68/105 (65%) 65/105 (62%) 94/105 (90%) 92/105 (88%) 95/105 (90%)
Normal Mucosa Matching CRC Validation
Set
42/105 (40%) 2/105 (2%) 0/105 (0%) 0/105 (0%) 3/105 (3%) 0/105 (0%) 4/105 (4%)
CRCs Combined (Test and Validation
Sets)
169/179
(94%)
142/179
(79%)
117/179
(65%)
119/179
(66%)
162/179
(91%)
159/179
(89%)
168/179
(94%)
Normal Mucosa Test Set 1/51 (2%) 1/51 (2%) 0/51 (0%) 0/51 (0%) 1/51 (2%) 1/51 (2%) 1/51 (2%)
Normal Mucosa Validation Set 5/59 (8%) 0/59 (0%) 0/59 (0%) 0/59 (0%) 1/59 (2%) 0/59 (0%) 1/59 (2%)
Normals Combined (Test and
Validation Sets)
6/110 (5%) 1/110 (1%) 0/110 (0%) 0/110 (0%) 2/110 (2%) 1/110 (1%) 2/110 (2%)
Abbreviation: CRC, colorectal cancer.
* Colon Cancer Cell lines have been analyzed using qualitative methylation-specific PCR.
§ Previously published results [9].
† Simultaneous methylation of two or more of the six markers provides a positive biomarker panel.
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status (only two MSI positive), tumor location, polyp size,
or patient age or sex (Table 4). For adenomas, the AUC
value of the combined test and validation sets was 0.968
(P = 2.6E-33; Figure 5; Additional file 1, Table S3).
Validation of promoter methylation status by direct
bisulfite sequencing
Methylation status of representative samples was con-
firmed by direct bisulfite sequencing using primers that
flank the MSP and qMSP regions of CNRIP1, FBN1,
INA, and SNCA (Figure 6).
Promoter methylation in relation to gene expression
In order to examine the relationship of aberrant promo-
ter methylation to gene expression, cancer cell lines, col-
orectal cancers, and normal mucosa samples were
subjected to quantitative real time analysis. The methy-
lation status of CNRIP1, FBN1, INA,a n dSNCA across
all cancer cell lines (n = 49) can be seen in Additional
file1, Figure S1. The level of mRNA expression of
CNRIP1, FBN1, INA,a n dSNCA was strongly associated
with promoter methylation status in cancer cell lines (P
= 0.037, P =0 . 0 1 7 ,P =0 . 0 0 6 ,a n dP =0 . 0 0 1 ,r e s p e c -
tively; Figure 7A).
Analysis of tissue samples supported that DNA pro-
moter methylation was significantly associated with
reduced gene expression for CNRIP1, INA,a n dSNCA
(Additional file 1, Table S4). The mean mRNA expres-
sion of FBN1 in methylated samples was lower than in
unmethylated samples (0.4 versus 0.8), although this was
not statistically significant (P = 0.125)
An association between promoter DNA methylation
and gene expression was further confirmed by measure-
ments of mRNA levels in colon cancer cell lines treated
with epigenetic drugs (both 5-aza-2’deoxycytidine and
trichostatin A, alone and in combination). Before drug
treatment all colon cancer cell lines tested harbored
promoter methylation of CNRIP1, INA, FBN1,a n d
SNCA accompanied by little or no expression of the
same genes. With the exception of FBN1,t h em R N A
levels of all genes subjected to real-time PCR analysis
were up-regulated in a least four of the six treated cell
lines (Figure 7B). The combined results from real-time
analyses using both in vivo as well as in vitro samples
thereby suggest that CNRIP1, INA,a n dSNCA gene
expression might be subjected to epigenetic regulation.
Discussion
We have identified four genes, CNRIP1, FBN1, INA,
and SNCA that were frequently hypermethylated in
colorectal adenomas and cancers. The methylation was
highly tumor-specific, as only a minority of normal
mucosa samples harbored promoter hypermethylation
Figure 3 Percent methylated reference (PMR) values of all
biomarkers in combined test and validation sets of normal
mucosa, adenomas, and colorectal cancer. Note that for SPG20
two outliers (PMR > 150) are excluded from the graph. The SPG20
promoter methylation status has previously been published in the
same sample series [9].
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Page 7 of 15of the same genes, fulfilling the criteria for cancer-spe-
cific methylation (type C) defined by Toyota and co-
workers [34]. These genes in combination with the
previously reported MAL [21,22] and SPG20 [9]
resulted in a biomarker panel with a sensitivity of 94%
for colorectal cancers and 93% for adenomas, and a
specificity of 98%. A high specificity will increase the
positive predictive value in screening and thereby limit
the number of false positives and subsequent unneces-
sary colonoscopies.
The use of genome-wide experimental approaches
for identification of novel target genes for tumor-speci-
fic DNA methylation has provided long candidate gene
lists [35-38], and a substantial number of genes has
been analyzed in detail, i.e. [36,39,40]. In spite of this,
only few genes, including GALR2, ITGA4, NTRK2,
OSMR, SFRP1, SFRP2, SLC16A12, TUBG2, MAL and
NMDAR2A [8,14,21,22,36,41-43] (reviewed in [44] and
[15]) have been found to harbor promoter methylation
in more than 80% of colorectal cancers analyzed, and
simultaneously in less than 10% of normal mucosa
samples, opening up the possibility of achieving high
sensitivities and specificities in a future test. Up to
now, only a few of the markers mentioned above have
been analyzed in non-invasive sample material
[13,14,42,45-47]. Additionally, the promising biomar-
kers SEPT9 [48] and VIM [12] have been analyzed in
blood/serum samples and stool samples, respectively
and are the only markers included in currently avail-
able non-invasive tests. Vimentin is the target gene of
the ColoSure™ test, which has a company-reported
sensitivity and specificity range of 72-77% and 83-94%,
Table 3 Promoter hypermethylation of biomarkers in colorectal carcinomas (test and validation sets) compared with
the patients clinico-pathological features and tumor phenotype
CNRIP1 FBN1 INA MAL SNCA Panel
MUMUMUMUMU P o s N e g
Tumors
No 169/179 10/179 142/179 37/179 117/179 62/179 162/179 17/179 119/179 60/179 168/179 11/179
Tumor phenotype
MSI 47 1 42 6 36 11 46 2 37 10 47 1
MSS 122 9 100 31 81 51 116 15 82 50 121 10
P value NS NS 7.4E-2 NS 7.6E-2 NS
BRAF ex15
Wild Type 136 10 109 37 87 59 129 17 89 57 135 11
Mutation 33 0 33 0 30 3 33 0 30 3 33 0
P value NS 2.5E-4 4.5E-4 3.9E-2 8.5E-4 NS
Sex
Male 83 6 71 18 57 32 81 8 57 32 81 8
Female 86 4 71 19 60 30 81 9 62 28 87 3
P value NS NS NS NS NS NS
Tumor site - 2 groups
Proximal 67 3 57 13 53 17 65 5 50 20 66 4
Distal 100 7 83 24 63 44 95 12 67 40 100 7
P value NS NS 2.4E-2 NS NS NS
Tumor site - 3 groups
Right 67 3 57 13 53 17 65 5 50 20 66 4
Left 57 0 48 9 36 21 54 3 39 18 57 0
Rectum 43 7 35 15 27 23 41 9 28 22 43 7
P value 6.1E-3 NS 4.3E-2 5.5E-2 NS 1.1E-2
Stage
I 27 3 23 7 19 11 26 4 20 10 27 3
II 76 3 60 19 54 25 72 7 52 27 75 4
III 45 4 42 7 31 18 44 5 33 16 45 4
IV 21 0 17 4 13 8 20 1 14 7 21 0
P value NS NS NS NS NS NS
Pearson’s chi-square and Fisher’s exact tests were used to calculate P-values. Associations between SPG20 promoter hypermethylation and tumor phenotype
have been published elsewhere [9].
Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; Neg, biomarker panel negative; NS, not significant; Pos, biomarker panel positive. A
positive biomarker panel is defined as methylation of two or more of the following biomarkers: CNRIP1, FBN1, INA, MAL, SNCA and SPG20.
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Page 8 of 15respectively. SEPT9 is the target gene of the plasma
based Epi ProColon early detection assay which can
detect 68%-72% of colorectal cancers with a specificity
of 89%-93% [48]. Despite that the first test analyzes
stool samples and the second test is blood based, the
sensitivity and specificity measurements are quite com-
parable, both leaving room for improvements. This is
underscored by an independent report finding
vimentin methylation in only 72% of colorectal cancers
a n di na sm u c ha s1 1 %o fn o r m a lm u c o s as a m p l e s
[39]. In the present study, four of the biomarkers
(CNRIP1, FBN1, MAL,a n dSPG20)w e r em o r ef r e -
quently methylated in colorectal cancers than pre-
viously reported for the vimentin gene, and
additionally less frequently methylated in normal
mucosa samples, underscoring the suitability of these
Table 4 Promoter hypermethylation of biomarkers in colorectal adenomas (test and validation sets) compared with
the patients clinico-pathological features and tumor phenotype
CNRIP1 FBN1 INA MAL SNCA Panel
M UMUMUMUMUP o s N e g
Tumors
No 101/111 10/111 77/111 34/111 39/111 72/111 93/111 18/111 59/111 52/111 103/111 8/111
Tumor phenotype
M S I 2 020112011 20
MSS 52 6 39 19 24 34 49 9 32 26 52 6
P value NS NS NS NS NS NS
Sex
Male 50 4 41 13 22 32 46 8 31 23 51 3
Female 51 6 36 21 17 40 47 10 28 29 52 5
P value NS NS NS NS NS NS
Tumor site - 2 groups
Proximal 15 2 11 6 5 12 14 3981 5 2
Distal 85 7 64 28 33 59 77 15 50 42 86 6
P value NS NS NS NS NS NS
Tumor site - 3 groups
Right 15 2 11 6 5 12 14 3981 5 2
Left 54 6 37 23 17 43 49 11 31 29 55 5
Rectum 31 1 27 5 16 16 28 4 19 13 31 1
P value NS 7.5E-2 NS NS NS NS
Dysplasia
High 7 052257052 70
Low 94 10 72 32 37 67 86 18 54 50 96 8
P value NS NS NS NS NS NS
Tumor size
< 10 mm 45 2 31 16 12 35 39 8 23 24 44 3
≥ 1 0 m m 5 5 7 4 41 82 63 65 21 03 62 6 5 7 5
P value NS NS NS NS NS NS
Pearson’s chi-square and Fisher’s exact tests were used to calculate P-values. Associations between SPG20 promoter hypermethylation and tumor phenotype
have been published elsewhere [9].
Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; Neg, biomarker panel negative; NS, not significant; Pos, biomarker panel positive. A
positive biomarker panel is defined as methylation of two or more of the following biomarkers: CNRIP1, FBN1, INA, MAL, SNCA and SPG20.
Figure 4 Summary of genetic and epigenetic findings in colorectal cancers (test and validation sets). Red color: methylated (CNRIP1,
FBN1, INA, MAL, SNCA, and/or SPG20), mutated (BRAF), and/or MSI positive samples. Green color: unmethylated, wt (BRAF), and/or MSS/MSI-low
samples. Biomarker panel positive samples have co-methylation of two or more of the six biomarkers. The SPG20 promoter methylation status
has previously been published in the same sample series [9].
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Page 9 of 15markers for diagnostic use. The most important results
in the present study is, however, the high performance
of the combined biomarker panel and the robustness
such a panel offers in a future test compared to single
markers.
As expected, the identified methylation markers were
frequently detected in MSI positive colorectal cancers
containing BRAF mutations, features that are consistent
with the CIMP positive phenotype [34]. However, due
to the broad coverage of the present biomarker panel,
Figure 5 Receiver Operating Characteristics (ROC) curves for methylation of individual and combined biomarkers in colorectal cancers
and adenomas versus normal mucosa (test and validation sets). The area under the ROC curve (AUC) signifies the accuracy of the
individual and combined biomarkers for distinguishing colorectal cancers (A and C) and adenomas (B and D) from normal colorectal tissue
samples. A) Colorectal cancers versus controls for individual biomarkers. B) Adenomas versus controls for individual biomarkers. All six biomarkers
are combined in C) Colorectal cancers versus controls and D) adenomas versus controls. Asymptotic significance, standard error and 95%
confidence interval measurements for all values can be found in Additional file 1, Table S3. The ROC curves for the SPG20 biomarker has been
published previously in the same sample series [9].
Lind et al. Molecular Cancer 2011, 10:85
http://www.molecular-cancer.com/content/10/1/85
Page 10 of 15Figure 6 Direct bisulfite sequencing of CNRIP1, FBN1, INA, and SNCA confirmed methylation status as assessed by methylation-specific
polymerase chain reaction (MSP).A )CNRIP1.B )FBN1.C )INA.D )SNCA. For all panels, the upper part is a schematic presentation of the CpG
sites (vertical bars) amplified by the bisulfite sequencing primers (110 to 470, NM_015463; -85 to 325, NM_000138; -110 to 71, NM_032727; and
-169 to 91, NM_000345, respectively). The transcription start site is represented by +1 and the arrows indicate the location of the MSP and qMSP
primers. For the lower part of the panels, black circles represent methylated CpGs (the presence of more than 80% cytosine); white circles
represent unmethylated CpGs (0 to 20% cytosine); and gray circles represent partially methylated sites (20-80% cytosine). The column of U, M,
and U/M at the right side of this lower part lists the methylation status of the respective cell lines as assessed by us using MSP analyses. The
transcription start point of CNRIP1 is here according to hg17 NM_015463. When the gene was annotated the transcription start point was
moved 340 bases upstream of the indicated position. Abbreviations: MSP, methylation-specific polymerase chain reaction; s, sense; as, antisense;
p, probe; U, unmethylated; M, methylated; U/M, presence of both unmethylated and methylated band.
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Page 11 of 15not only cancers harboring these features were biomar-
ker positive, but also the majority of MSS tumors with
wild-type BRAF. It is essential that a diagnostic biomar-
ker panel adequately “represents” the entire large bowel,
in order to detect all pheno- and geno-typically different
colorectal tumors. The present biomarker panel is posi-
tive in tumors independent of the patient’sg e n d e ra n d
age, as well as of tumor stage and location. Even though
tumors of all clinico-pathological subtypes were repre-
sented among the biomarker panel methylation positive
samples, the very few negative colorectal cancers were
generally of the MSS phenotype and were BRAF wild-
type, compatible with CIMP negative tumors [34]. How-
ever, it should be noted that in the present study we
have used the test sets to establish the most optimal
threshold for each biomarker assay (resulting in the
highest specificity). From these values, we chose the
highest and most conservative scoring threshold (per-
centage methylated sample - PMR value) and applied
this to all biomarkers. Alternatively, by setting the
threshold for each individual gene, the sensitivity could
be increased without necessarily affecting the specificity.
I ns p i t eo fs e v e r a lg e n o m e - w i d ee p i g e n e t i cs t u d i e s ,
only a few reports include DNA methylation data and
potential subsequent epigenetic silencing of CNRIP1,
FBN1, INA,a n dSNCA in cancer [10,49-53]. Due to the
exceptionally high methylation frequencies of these
genes in colorectal tumors they are suitable as biomar-
kers, but the potential roles of the encoded proteins in
tumor genesis remain unknown. Interestingly, mutations
in FBN1, which is a member of the fibrillin family, are
associated with the Marfan syndrome [49]. FBN1 methy-
lation has previously been identified in prostate cancer
cell lines [50] and the gene has also been shown to be
epigenetically silenced in tumor endothelial cells [51].
Functional validation by RNA interference in endothelial
cells pinpointed FBN1 as a negative regulator of cell
growth and angiogenesis [51]. The expression of the
synuclein alpha gene, SNCA, was recently shown to be
regulated by methylation and decreased in the brain tis-
sue of patients with Parkinsons’sd i s e a s e[ 5 2 ] .T h eg e n e
has also been reported methylated in 38% of breast can-
cer tumors [53]. Interestingly, the majority of adjacent
normal tissue samples were also found to be methylated,
indicating a potential field defect that could help pin-
pointing geographical zones of increased breast cancer
risk [53]. Such a field defect was not seen in the present
study for SNCA, where all normal mucosa samples
taken in distance from the colorectal cancers were
unmethylated. In contrast, we observed a 40% promoter
methylation frequency of CNRIP1 in the same sample
group. The majority of normal mucosa samples from
colorectal cancer free individuals (95%) were unmethy-
lated in the CNRIP1 gene promoter. The methylation
positive normal mucosa cells adjacent to the methylated
cancer could potentially increase the detection of this
aberration in stool samples, by increasing the total num-
ber of methylation positive cells shed into the lumen. In
2006 we identified CNRIP1 as a promoter methylation
target in colorectal cancer by treatment of cell lines
with 5-aza 2’deoxycytidine followed by expression
microarray analyses [20,54]. By applying DNA methyla-
tion microarray analysis and subsequent methylation-
sensitive high resolution melting analysis colorectal
tumor specific promoter methylation of CNRIP1 was
recently confirmed [10]. Most of the adenomas (n = 12)
and carcinomas (n = 55) analyzed were methylated [10]
in agreement with the present report, underscoring the
potential of CNRIP1 as a novel marker for early detec-
tion of colorectal tumors.
Figure 7 Real-time PCR analysis of SNCA in cancer cell lines
with known methylation status. A) Gene expression and DNA
promoter methylation status of SNCA in cancer cell lines. The
quantitative gene expression levels are displayed as ratios between
the median of SNCA and the average of two endogenous controls,
GUSB and ACTB. *Partially methylated signifies cell lines with the
presence of both a methylated and unmethylated band for the MSP
analysis, which most likely reflect monoallelic or heterogeneous
methylation. B) Relative gene expression of SNCA in six colon cancer
cell lines treated with 1 μM of 5-aza-2’deoxycytidine for 72 h (AZA),
0.5 μM of trichostatin A for 12 h (TSA), and a combination of both
drugs (AZA+TSA).
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Page 12 of 15Here we found that the DNA methylation of CNRIP1,
FBN1, INA,a n dSNCA was associated with reduced or
lost gene expression in cell lines, indicating that they
might harbor a tumor suppressor function. Down-regu-
lation in colorectal cancers compared with normal
mucosa was also seen for all genes from in silico ana-
lyses, including MAL and SPG20, using the GeneSapiens
website, which contains Affymetrix gene expression
array experiments representing more than 500 colorectal
cancers and 23 normal colon samples [55].
Conclusions
In the present study we identified and validated four
novel methylated genes with high sensitivity and specifi-
city for both colorectal cancers and adenomas. A combi-
nation of these and two of our previously identified
biomarkers (MAL [21,22] and SPG20 [9]) provided an
excellent biomarker panel. Early detection of colorectal
cancer, at a stage where it is localized and curable will
contribute substantially to reduce mortality due to the
disease. Moreover, the present biomarker panel has
been shown to also be positive in premalignant adeno-
mas. Therefore, a test using this panel may also provide
non-invasive detection of lesions prior to malignancy,
thereby potentially reducing the incidence of colorectal
cancer. The advantage of a marker panel compared to
single marker analysis is obviously the higher sensitivity
and specificity but also increased robustness. A single
marker will be more prone to biological and/or techni-
cal failure than a combined panel. Finally, the benefit of
a non-invasive epigenetic test compared to a genetic test
is the simplicity of performance, which is expected to
lower the costs, hence supporting it as appropriate for
screening purposes. The presented biomarker panel
seems highly suitable for development of a non-invasive
test for early detection of colorectal tumors.
Additional material
Additional file 1: Supplemental tables.
Additional file 2: Figure S1. Summary of methylation-specific
polymerase chain reaction (MSP) results in cancer cell lines. Red
color indicates methylated sample, orange color indicates the presence
of both methylated and unmethylated bands, green color indicates
unmethylated sample, and grey color indicates samples that were not
successfully amplified/analyzed. The upper part of the figure illustrates
the results from colon cancer cell lines (n = 20) and the lower part of
the figure from cell lines originating from various cancer tissues (n = 29).
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